MK-1454
Total Payments
$5.7M
Transactions
1,036
Doctors
8
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.7M | 645 | 5 |
| 2019 | $1.9M | 161 | 1 |
| 2018 | $1.6M | 149 | 3 |
| 2017 | $496,560 | 81 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.7M | 1,009 | 99.8% |
| Consulting Fee | $9,325 | 27 | 0.2% |
Payments by Type
Research
$5.7M
1,009 transactions
General
$9,325
27 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injectionas Monotherapy and in Combination with Pembrolizumab for Patients withAdvanced,Metastatic Solid Tumors or Lymphomas | Merck Sharp & Dohme Corporation | $3.5M | 0 |
| Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab for Patients with Advanced,Metastatic Solid Tumors or Lymphomas | Merck Sharp & Dohme Corporation | $1.4M | 0 |
| Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injectionas Monotherapy and in Combination with Pembrolizumab for Patients withAdvanced/Metastatic Solid Tumors or Lymphomas | Merck Sharp & Dohme Corporation | $406,154 | 0 |
| A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination with IV Pembrolizumab vs IV Pembrolizumab Monotherapy | Merck Sharp & Dohme Corporation | $326,369 | 0 |
| Ph1, Open-Label, Multicenter Study with MK-1454 in Solid Tumors | Merck Sharp & Dohme Corporation | $572.00 | 0 |
| A Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-0482 as monotherapy and in combination with pembrolizumab in participants with advanced,metastatic solid tumors. | Merck Sharp & Dohme Corporation | $191.75 | 0 |
Top Doctors Receiving Payments for MK-1454
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Dallas, TX | $5.7M | 1,009 |
| , MD | Body Imaging | Newton, MA | $3,300 | 1 |
| , M.D | Neuroradiology | Stockton, CA | $1,245 | 4 |
| , MD | Diagnostic Radiology | Ames, IA | $1,200 | 5 |
| , MD | Diagnostic Radiology | Boston, MA | $1,080 | 5 |
| , M.D., M.H.S | Internal Medicine | Boston, MA | $830.00 | 3 |
| , MD PHD | Diagnostic Radiology | Baltimore, MD | $600.00 | 3 |
| , MD | Diagnostic Radiology | Boston, MA | $600.00 | 3 |
| , MD PHD | Diagnostic Radiology | Boston, MA | $470.00 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $5.7M
- Total Doctors 8
- Transactions 1,036
About MK-1454
MK-1454 is a drug associated with $5.7M in payments to 8 healthcare providers, recorded across 1,036 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $1.7M was paid across 645 transactions to 5 doctors.
The most common payment nature for MK-1454 is "Unspecified" ($5.7M, 99.8% of total).
MK-1454 is associated with 6 research studies, including "Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injectionas Monotherapy and in Combination with Pembrolizumab for Patients withAdvanced,Metastatic Solid Tumors or Lymphomas" ($3.5M).